CoChat

Gastric bypass versus best medical treatment for diabetic kidney disease: 5 years follow up of a single-centre open label randomised controlled trial

Open access
Cohen, Ricardo V., Pereira, Tiago Veiga, Aboud, Cristina Mamédio, Zanata Petry, Tarissa Beatrice, Lopes Correa, José Luis, Schiavon, Carlos Aurélio, Pompílio, Carlos Eduardo, Quirino Pechy, Fernando Nogueira, Calmon da Costa Silva, Ana Carolina, Cunha da Silveira, Lívia Porto, Paulo de Paris Caravatto, Pedro, Halpern, Helio, de Lima Jacy Monteiro, Frederico, da Costa Martins, Bruno, Kuga, Rogerio, Sarian Palumbo, Thais Mantovani, Friedman, Allon N., le Roux, Carel W. · 2022 · eClinicalMedicine
Cited by 41

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Background: We compared the albuminuria-lowering effects of Roux-en-Y gastric bypass (RYGB) to best medical treatment in patients with diabetic kidney disease and obesity to determine which treatment is better. Methods: A 5 year, open-label, single-centre, randomised trial studied patients with diabetic kidney disease and class I obesity after 1:1 randomization to best medical treatment (n = 49) or RYGB (n = 51). The primary outcome was the proportion of patients achieving remission of microalbuminuria after 5 years. Secondary outcomes included improvements in diabetic kidney disease, glycemic control, quality of life, and safety. For efficacy outcomes, we performed an intention-to-treat (ITT) analysis. This study was registered with ClinicalTrials.gov, NCT01821508. Findings: 88% of patients (44 per arm) completed 5-year follow-up. Remission of albuminuria occurred in 59.6% (95% CI = 45.5-73.8) after best medical treatment and 69.7% (95% CI = 59.6-79.8) after RYGB (risk difference: 10%, 95% CI, -7 to 27, P = 0.25). Patients after RYGB were twice as likely to achieve an HbA1c ≤ 6.5% (60.2% versus 25.4%, risk difference, 34.9%; 95% CI = 15.8-53.9, P < 0.001). Quality of life after five years measured by the 36-Item Short Form Survey questionnaire (standardized to a 0-to-100 scale) was higher in the RYGB group than in the best medical treatment group for several domains. The mean differences were 13.5 (95% CI, 5.5-21.6, P = 0.001) for general health, 19.7 (95% CI, 9.1-30.3, P < 0.001) for pain, 6.1 (95% CI, -4.8 to 17.0, P = 0.27) for social functioning, 8.3 (95% CI, 0.23 to 16.3, P = 0.04) for emotional well-being, 12.2 (95% CI, 3.9-20.4, P = 0.004) for vitality, 16.8 (95% CI, -0.75 to 34.4, P = 0.06) for mental health, 21.8 (95% CI, 4.8-38.7, P = 0.01) for physical health and 11.1 (95% CI, 2.24-19.9, P = 0.01) for physical functioning. Serious adverse events were experienced in 7/46 (15.2%) after best medical treatment and 11/46 patients (24%) after RYGB (P = 0.80). Interpretation: Albuminuria remission was not statistically different between best medical treatment and RYGB after 5 years in participants with diabetic kidney disease and class 1 obesity, with 6-7 in ten patients achieving remission of microalbuminuria (uACR <30 mg/g) in both groups. RYGB was superior in improving glycemia, diastolic blood pressure, lipids, body weight, and quality of life. Funding: The study was supported by research grants from Johnson & Johnson Brasil, Oswaldo Cruz German Hospital, and by grant 12/YI/B2480 from Science Foundation Ireland (Dr le Roux) and grant 2015-02733 from the Swedish Medical Research Council (Dr le Roux). Dr Pereira was funded by the Chevening Scholarship Programme (Foreign and Commonwealth Office, UK).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.eclinm.2022.101725

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 41

Metadata

Authors
Cohen, R. V., Pereira, T. V., Aboud, C. M., Zanata Petry, T. B., Lopes Correa, J. L., Schiavon, C. A., Pompílio, C. E., Quirino Pechy, F. N., Calmon da Costa Silva, A. C., Cunha da Silveira, L. P., Paulo de Paris Caravatto, P., Halpern, H., de Lima Jacy Monteiro, F., da Costa Martins, B., Kuga, R., Sarian Palumbo, T. M., Friedman, A. N., & le Roux, C. W.
Venue
eClinicalMedicine
Publisher
Elsevier BV
Published
2022-11
Volume
53
Pages
101725
ISSN
2589-5370 (ISSN-L)
OpenAlex
W4308930021
Cited by
41
References
12
FWCI
6.99
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Gastric bypass versus best medical treatment for diabetic kidney disease: 5 years follow up of a single-centre open label randomised controlled trial. https://app.cochat.ai/papers/10.1016/j.eclinm.2022.101725
The paper
Cohen, R. V., Pereira, T. V., Aboud, C. M., Zanata Petry, T. B., Lopes Correa, J. L., Schiavon, C. A., Pompílio, C. E., Quirino Pechy, F. N., Calmon da Costa Silva, A. C., Cunha da Silveira, L. P., Paulo de Paris Caravatto, P., Halpern, H., de Lima Jacy Monteiro, F., da Costa Martins, B., Kuga, R., Sarian Palumbo, T. M., Friedman, A. N., & le Roux, C. W. (2022). Gastric bypass versus best medical treatment for diabetic kidney disease: 5 years follow up of a single-centre open label randomised controlled trial. eClinicalMedicine. https://doi.org/10.1016/j.eclinm.2022.101725

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.